» Articles » PMID: 15626901

Ribosomal DNA Sequence Analysis of Mucosa-associated Bacteria in Crohn's Disease

Overview
Specialty Gastroenterology
Date 2005 Jan 1
PMID 15626901
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Enteric bacteria are implicated in the pathogenesis of Crohn's disease (CD); however, no specific causative organisms have been identified.

Aims: This study was undertaken to correlate disease activity with changes in intestinal biota in patients with CD.

Subjects: Ribosomal DNA analysis was used to explore the composition of the intestinal biota in patients with (1) CD undergoing colonoscopy, (2) CD undergoing surgical resection, and (3) no inflammatory bowel disease.

Methods: Primers targeting bacterial 16S ribosomal DNA (rDNA) were used to amplify bacterial DNA associated with active CD lesions, comparable normal tissue from patients with CD, and normal control tissue. Each amplicon was cloned. Seven hundred thirty-nine rDNA clones were sequenced from 16 biopsies from CD patients, 15 surgical samples, and 10 biopsies from normal control patients.

Results: Known extracellular or intracellular pathogens were not found. No rDNA sequence, phylogenetic group, or subgroup was consistently associated with CD lesions compared with normal tissues from the same patients. Colonic biopsies from CD-afflicted patients compared with biopsies from normal control subjects had an increase in facultative bacteria; in small bowel, CD patients had an increase in the Ruminococcus gnavus subgroup with a decrease in the Clostridium leptum and Prevotella nigrescens subgroups. However, differences in small bowel may have reflected individual variation rather than disease association. Surgical samples showed differences when compared with biopsy-derived samples.

Conclusions: These findings suggest that CD is not caused by invasive pathogens associated specifically with the sites of lesions but that dysbiosis exists in this condition.

Citing Articles

Goblet cells: guardians of gut immunity and their role in gastrointestinal diseases.

Tonetti F, Eguileor A, Llorente C eGastroenterology. 2024; 2(3).

PMID: 39524932 PMC: 11542612. DOI: 10.1136/egastro-2024-100098.


Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities.

Jandl B, Dighe S, Gasche C, Makristathis A, Muttenthaler M Clin Microbiol Rev. 2024; 37(3):e0013323.

PMID: 38995034 PMC: 11391705. DOI: 10.1128/cmr.00133-23.


Mapping the geographical distribution of the mucosa-associated gut microbiome in GI-symptomatic children with autism spectrum disorder.

Reeves K, Figuereo Y, Weis V, Hsu F, Engevik M, Krigsman A Am J Physiol Gastrointest Liver Physiol. 2024; 327(2):G217-G234.

PMID: 38887795 PMC: 11637567. DOI: 10.1152/ajpgi.00101.2024.


An Update on the Role and Potential Molecules in Relation to in Inflammatory Bowel Disease, Obesity and Diabetes Mellitus.

Hong J, Fu T, Liu W, Du Y, Bu J, Wei G Diabetes Metab Syndr Obes. 2024; 17:1235-1248.

PMID: 38496006 PMC: 10942254. DOI: 10.2147/DMSO.S456173.


Mucin glycans and their degradation by gut microbiota.

Yamaguchi M, Yamamoto K Glycoconj J. 2023; 40(4):493-512.

PMID: 37318672 DOI: 10.1007/s10719-023-10124-9.